Eventide Asset Management LLC Sells 152,723 Shares of Dyne Therapeutics, Inc. (NASDAQ:DYN)

Eventide Asset Management LLC reduced its position in shares of Dyne Therapeutics, Inc. (NASDAQ:DYN) by 31.5% in the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 332,277 shares of the company’s stock after selling 152,723 shares during the period. Eventide Asset Management LLC owned 0.33% of Dyne Therapeutics worth $11,935,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also bought and sold shares of DYN. FMR LLC lifted its position in Dyne Therapeutics by 69.7% during the third quarter. FMR LLC now owns 9,026,697 shares of the company’s stock valued at $324,239,000 after buying an additional 3,707,734 shares during the period. Price T Rowe Associates Inc. MD increased its position in Dyne Therapeutics by 8,284.6% during the first quarter. Price T Rowe Associates Inc. MD now owns 1,132,092 shares of the company’s stock valued at $32,141,000 after acquiring an additional 1,118,590 shares during the last quarter. Vanguard Group Inc. increased its position in shares of Dyne Therapeutics by 47.7% during the 1st quarter. Vanguard Group Inc. now owns 3,440,270 shares of the company’s stock valued at $97,669,000 after purchasing an additional 1,110,629 shares during the last quarter. First Light Asset Management LLC increased its holdings in Dyne Therapeutics by 261.0% during the second quarter. First Light Asset Management LLC now owns 382,433 shares of the company’s stock valued at $13,496,000 after buying an additional 276,485 shares during the last quarter. Finally, Marshall Wace LLP increased its stake in shares of Dyne Therapeutics by 409.4% in the 2nd quarter. Marshall Wace LLP now owns 273,567 shares of the company’s stock worth $9,654,000 after purchasing an additional 219,862 shares in the last quarter. Hedge funds and other institutional investors own 96.68% of the company’s stock.

Insider Buying and Selling at Dyne Therapeutics

In other news, Director Carlo Incerti sold 16,500 shares of the business’s stock in a transaction on Monday, November 18th. The stock was sold at an average price of $28.73, for a total value of $474,045.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Jason P. Rhodes sold 782 shares of Dyne Therapeutics stock in a transaction on Thursday, November 14th. The shares were sold at an average price of $33.10, for a total value of $25,884.20. Following the completion of the sale, the director now directly owns 15,962 shares of the company’s stock, valued at approximately $528,342.20. This represents a 4.67 % decrease in their position. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 176,257 shares of company stock worth $6,193,718. 20.77% of the stock is currently owned by insiders.

Dyne Therapeutics Price Performance

DYN stock opened at $31.13 on Friday. Dyne Therapeutics, Inc. has a 1 year low of $10.12 and a 1 year high of $47.45. The firm has a market capitalization of $3.17 billion, a P/E ratio of -8.74 and a beta of 1.10. The business’s 50-day moving average is $31.78 and its two-hundred day moving average is $35.36.

Dyne Therapeutics (NASDAQ:DYN) last released its quarterly earnings results on Tuesday, November 12th. The company reported ($0.96) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.71) by ($0.25). On average, analysts expect that Dyne Therapeutics, Inc. will post -3.45 EPS for the current year.

Analyst Upgrades and Downgrades

Several brokerages have recently commented on DYN. StockNews.com downgraded shares of Dyne Therapeutics from a “hold” rating to a “sell” rating in a research report on Monday, September 16th. JPMorgan Chase & Co. lowered shares of Dyne Therapeutics from an “overweight” rating to a “neutral” rating and lowered their price objective for the company from $43.00 to $35.00 in a research report on Thursday, October 24th. Royal Bank of Canada started coverage on Dyne Therapeutics in a report on Tuesday. They issued an “outperform” rating and a $45.00 target price for the company. Stifel Nicolaus lifted their price target on shares of Dyne Therapeutics from $41.00 to $66.00 and gave the stock a “buy” rating in a research note on Friday, August 16th. Finally, Oppenheimer reaffirmed an “outperform” rating and issued a $55.00 price objective on shares of Dyne Therapeutics in a research report on Tuesday, September 3rd. One investment analyst has rated the stock with a sell rating, one has given a hold rating, nine have given a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat.com, Dyne Therapeutics currently has a consensus rating of “Moderate Buy” and a consensus target price of $50.82.

Dyne Therapeutics Profile

Dyne Therapeutics, Inc, a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics.